Dermata Therapeutics Inc. (DRMA)
0.91
-0.02 (-2.38%)
At close: Apr 04, 2025, 10:16 AM
Company Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.
The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions.
The company was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald T. Proehl |
Contact Details
Address: 3525 Del Mar Heights Road San Diego, California United States | |
| Website | https://www.dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001853816 |
| CUSIP Number | 249845108 |
| ISIN Number | US2498453065 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President & Chief Financial Officer |
| David F. Hale | Co-Founder & Lead Independent Director |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President & Chief Development Officer |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Sean Proehl | Associate General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 13, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 05, 2025 | 424B3 | Filing |
| Feb 04, 2025 | D/A | [Amend] Filing |